The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
秋风
DW
无极微光
Enigma_GEB
xing_xing
cdercder
Zhou
嘉心糖
aajhajkahna
OK
老的火龙果
经十路以东
Criminology34
coolru
渡人舟
七听
拆迁办禁言
牧青
贪玩的秋柔
皖公网安备34019202002308
